MX362478B - Derivado de benzoazepina novedoso y uso medico del mismo. - Google Patents

Derivado de benzoazepina novedoso y uso medico del mismo.

Info

Publication number
MX362478B
MX362478B MX2015008399A MX2015008399A MX362478B MX 362478 B MX362478 B MX 362478B MX 2015008399 A MX2015008399 A MX 2015008399A MX 2015008399 A MX2015008399 A MX 2015008399A MX 362478 B MX362478 B MX 362478B
Authority
MX
Mexico
Prior art keywords
group
lower alkyl
alkyl group
substituted
formula
Prior art date
Application number
MX2015008399A
Other languages
English (en)
Other versions
MX2015008399A (es
Inventor
Kitamoto Katsunori
Kasugai Nobuyoshi
Kataoka Hiroyo
Ohsawa Yasushi
Kuno Yuka
Fujieda Hiroki
Sakai Keita
Nagano Hiroki
Takahashi Naoki
Izuchi Toru
Takeuchi Mitsuaki
Kurumazuka Daisuke
Miyazawa Toshiyuki
Harada Satoko
Asano Yukiyasu
Yamada Yurie
Okabe Morio
Gotoh Izumi
Original Assignee
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co filed Critical Sanwa Kagaku Kenkyusho Co
Publication of MX2015008399A publication Critical patent/MX2015008399A/es
Publication of MX362478B publication Critical patent/MX362478B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objetivo de la invención actual es a proporcionar un compuesto que tenga una actividad agonista del receptor V2. Se proporciona una composición farmacéutica que contiene, como un ingrediente activo, un compuesto representado por la fórmula general (I) descrita enseguida: Fórmula 1 (ver Fórmula) en donde R1 es la fórmula descrita enseguida: Fórmula 2 (ver Fórmula) (en donde A es un grupo alquileno inferior que puede sustituirse con un grupo alquilo inferior, o similares; R6 es un átomo de hidrógeno, o similares; R7 es un grupo hidroxilo, un grupo heterocíclico aromático que puede sustituirse con un grupo alquilo inferior, un grupo carbamoilo, o similares); R2 es un átomo de hidrógeno o un grupo alquilo inferior; R3 es un grupo alquilo inferior que puede sustituirse con 1 hasta 3 átomos de flúor, o un átomo de halógeno; R4 es un grupo heterocíclico monocíclico aromático de cinco miembros, un grupo heterocíclico monocíclico no aromático de cinco miembros, o similares, (con la condición de que cada uno de estos grupos heterocíclicos contiene al menos un átomo de nitrógeno y puede sustituirse con un grupo alquilo inferior); y R5 es un grupo alquilo inferior, un átomo de halógeno, o similares, o una sal farmacológicamente aceptable del mismo.
MX2015008399A 2012-12-26 2013-12-26 Derivado de benzoazepina novedoso y uso medico del mismo. MX362478B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012281908 2012-12-26
PCT/JP2013/084937 WO2014104209A1 (ja) 2012-12-26 2013-12-26 新規ベンゾアゼピン誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2015008399A MX2015008399A (es) 2015-09-23
MX362478B true MX362478B (es) 2019-01-11

Family

ID=51021283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008399A MX362478B (es) 2012-12-26 2013-12-26 Derivado de benzoazepina novedoso y uso medico del mismo.

Country Status (15)

Country Link
US (1) US9586905B2 (es)
EP (1) EP2940008B1 (es)
JP (2) JP5968466B2 (es)
KR (1) KR101983880B1 (es)
CN (1) CN104884436B (es)
AU (1) AU2013367084B2 (es)
BR (1) BR112015015663A2 (es)
CA (1) CA2889239C (es)
DK (1) DK2940008T3 (es)
ES (1) ES2633981T3 (es)
HK (1) HK1208676A1 (es)
MX (1) MX362478B (es)
PL (1) PL2940008T3 (es)
RU (1) RU2642783C2 (es)
WO (1) WO2014104209A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362478B (es) * 2012-12-26 2019-01-11 Sanwa Kagaku Kenkyusho Co Derivado de benzoazepina novedoso y uso medico del mismo.
JP2022055368A (ja) * 2019-02-19 2022-04-08 株式会社三和化学研究所 ベンゾアゼピン誘導体の製造方法及びその中間体
JPWO2020171055A1 (es) * 2019-02-19 2020-08-27

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952573A (en) 1988-03-23 1990-08-28 Laboratoirs Alcon S.A. Compounds having GABA like activity, and use of same in tissue irrigating solutions
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5985869A (en) 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
WO1995034540A1 (en) 1994-06-15 1995-12-21 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2964031B2 (ja) * 1995-12-15 1999-10-18 大塚製薬株式会社 ベンゾアゼピン誘導体
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
JPH111456A (ja) 1997-06-13 1999-01-06 Otsuka Pharmaceut Co Ltd アミド誘導体
JP2926335B2 (ja) 1997-06-13 1999-07-28 大塚製薬株式会社 医薬組成物
DE60233251D1 (de) * 2001-11-16 2009-09-17 Astellas Pharma Inc 4,4-difluor-1,2,3,4-tetrahydro-5h-1-benzazepinderivate und deren salze
JP4238978B2 (ja) * 2003-04-22 2009-03-18 大塚製薬株式会社 ベンゾアゼピン化合物及びその製造法
ES2366641T3 (es) * 2003-04-28 2011-10-24 Astellas Pharma Inc. Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sal del mismo.
WO2005037795A2 (en) 2003-06-17 2005-04-28 Janssen Pharmaceutica N.V. Substituted spirobenzazepines
EP1867639A1 (en) * 2005-03-25 2007-12-19 Kissei Pharmaceutical Co., Ltd. Urea derivative, medicinal composition containing the same, and medicinal use of these
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
US8987252B2 (en) * 2007-05-10 2015-03-24 Albany Molecular Research, Inc. Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
PL2860175T3 (pl) * 2012-06-11 2018-07-31 Tacurion Sposób wytwarzania związku 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepinowego i związku pośredniego do jego syntezy
MX362478B (es) * 2012-12-26 2019-01-11 Sanwa Kagaku Kenkyusho Co Derivado de benzoazepina novedoso y uso medico del mismo.

Also Published As

Publication number Publication date
CN104884436B (zh) 2017-06-13
DK2940008T3 (en) 2017-08-07
JPWO2014104209A1 (ja) 2017-01-19
KR20150098614A (ko) 2015-08-28
CA2889239A1 (en) 2014-07-03
JP5968466B2 (ja) 2016-08-10
WO2014104209A1 (ja) 2014-07-03
EP2940008A4 (en) 2016-05-18
EP2940008B1 (en) 2017-05-17
JP2016199575A (ja) 2016-12-01
BR112015015663A2 (pt) 2017-07-11
AU2013367084B2 (en) 2017-06-08
US20150291533A1 (en) 2015-10-15
JP6231621B2 (ja) 2017-11-15
MX2015008399A (es) 2015-09-23
HK1208676A1 (en) 2016-03-11
CA2889239C (en) 2020-10-27
KR101983880B1 (ko) 2019-05-29
RU2015131020A (ru) 2017-01-30
CN104884436A (zh) 2015-09-02
PL2940008T3 (pl) 2017-10-31
EP2940008A1 (en) 2015-11-04
ES2633981T3 (es) 2017-09-26
RU2642783C2 (ru) 2018-01-26
AU2013367084A1 (en) 2015-05-28
US9586905B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX354102B (es) Derivados de bencimidazol-prolina.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MY167791A (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MY177250A (en) Novel nicotinamide derivative or salt thereof
MX2011007663A (es) Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2.
WO2012101065A3 (en) Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
MX2015008399A (es) Derivado de benzoazepina novedoso y uso medico del mismo.
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
FR2981933B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
FG Grant or registration